Novartis Venture Fund
Robin Gommers serves as the Site Head at Novartis in Baarle-Nassau, overseeing the production of GMP grade isotopes for Radio Ligand Therapies since January 2022. Prior to this role, Gommers spent 17 years at Amgen, where responsibilities included Director of Site Operations, focusing on manufacturing operations strategy and transformation, and leading various roles within the Corporate Transformation Office, including the management of enterprise architecture and portfolio management. Gommers has a strong background in continuous improvement, operational excellence, and clinical supply chain management, supported by a Master of Science in General Management from Nyenrode Business University and a Bachelor of Science in Industrial Engineering from Hogeschool Midden-Brabant. Previous consulting experience includes work with prominent clients such as DSM and Vopak, as well as early career roles in supply chain management.
This person is not in any teams
This person is not in any offices
Novartis Venture Fund
3 followers
Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. In their investments, they look for unmet need and clinical impact, novel proprietary science, and understanding of the mechanism, management, and board experience and capital efficiency in the program.